ELI LILLY AND COMPANY | 43,12 Euro | +0,475 +1,11 % | |
| WKN: 858560 ISIN: US5324571083 Ticker-Symbol: LLY | Frankfurt | 22.05.13 | 18:39 Uhr |
Branche PharmaAktienmarkt S&P 100S&P 500 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 22.05. | Corgenix Medical Collaborates With Eli Lilly To Develop Diagnostic Technology | 55 | AFX News | |
| INDIANAPOLIS (dpa-AFX) - Corgenix Medical Corp. (CONX.OB) announced that it
has entered into a collaboration agreement with Eli Lilly and Co.(LLY) to
develop diagnostic technology in support... Mehr lesen zu: Corgenix Medical Collaborates With Eli Lilly To Develop Diagnostic Technology | ||||
| 22.05. | Corgenix Announces Collaboration with Lilly | - | Benzinga.com | |
| 20.05. | Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar | 113 | Marketwired | |
| NEW YORK, NY -- (Marketwired) -- 05/20/13 -- The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner's treatment. Two biotechnology companies... Mehr lesen zu: Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar | ||||
| 20.05. | From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients | 26 | PR Newswire | |
| INDIANAPOLIS, May 20, 2013 /PRNewswire/ -- The many health care providers working at Eli Lilly and Company (NYSE:LLY) âˆ' including doctors, nurses, and pharmacists âˆ' play a vital role in bringing... Mehr lesen zu: From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients | ||||
| 20.05. | Red Cross volunteers and Lilly join forces to help diabetes patients better manage their disease | - | AME Info | |
| 17.05. | Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property | 82 | Bloomberg | |
| 16.05. | Canada Supreme Court Won't Hear Eli Lilly Zyprexa Appeal | 1 | Bloomberg | |
| 14.05. | Lilly Oncology to Release New Pipeline Data at ASCO 2013 | 44 | PR Newswire | |
| INDIANAPOLIS, May 14, 2013 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will present data from key molecules that make up its clinical oncology pipeline during the 49th Annual Meeting of the American... Mehr lesen zu: Lilly Oncology to Release New Pipeline Data at ASCO 2013 | ||||
| 14.05. | Lilly CEO Recovering From Surgery for Dilated Aorta | 1 | Euroinvestor | |
| 14.05. | Eli Lilly CEO John Lechleiter Undergoes Scheduled Surgery | 47 | AFX News | |
| INDIANAPOLIS (dpa-AFX) - Drugmaker Eli Lilly and Co. (LLY) Tuesday said John
Lechleiter, chairman, president and chief executive officer, underwent scheduled
surgery for a dilated aorta... Mehr lesen zu: Eli Lilly CEO John Lechleiter Undergoes Scheduled Surgery | ||||
| 14.05. | Lilly Provides Update on CEO Dr. John Lechleiter | 17 | PR Newswire | |
| INDIANAPOLIS, May 14, 2013 /PRNewswire/ --Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery... Mehr lesen zu: Lilly Provides Update on CEO Dr. John Lechleiter | ||||
| 14.05. | What Does This Failure Mean for Eli Lilly Investors? | 7 | Motley Fool | |
| 13.05. | Lilly Scraps Oncology Candidate | 3 | Zacks | |
| 13.05. | Eli Lilly enzastaurin Phase III study fails to meet primary endpoint | - | Pharma Bus Review | |
| 13.05. | XETR DIVIDEND INFORMATION - 14.05.2013 - 1 | 1.019 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 13.05.2013 CUM DIVIDENDE UND AM 14.05.2013
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 13.05.2013. THE
EX-DIVIDEND DAY WILL BE 14.05.2013.
... Mehr lesen zu: XETR DIVIDEND INFORMATION - 14.05.2013 - 1 | ||||
| 13.05. | XFRA DIVIDEND INFORMATION - 14.05.2013 - 1 | 390 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 13.05.2013 CUM DIVIDENDE UND AM 14.05.2013
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 13.05.2013. THE
EX-DIVIDEND DAY WILL BE 14.05.2013.
... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 14.05.2013 - 1 | ||||
| 10.05. | Lilly Stops Development Of Lymphoma Drug Enzastaurin As It Fails In Ph 3 Trial | 186 | AFX News | |
| INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said Friday that it will
stop development of its experimental cancer drug enzastaurin after the medicine
failed in a Phase III clinical trial... Mehr lesen zu: Lilly Stops Development Of Lymphoma Drug Enzastaurin As It Fails In Ph 3 Trial | ||||
| 10.05. | Eli Lilly ends development of lymphoma drug | 3 | Yahoo-USA | |
| 10.05. | Eli Lilly Ends Development of Lymphoma Drug Enzastaurin; Missed Study Endpoint | 1 | Euroinvestor | |
| 10.05. | Eli Lilly's lymphoma drug fails in late-stage trial | 1 | Reuters.com | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| PFIZER | 22,951 | +4,44 % | Pfizer spaltet Tierarzneisparte Zoetis endgültig ab |
| NOVARTIS | 58,42 | +0,97 % | Novartis hat kein Interesse an Actavis |
| GLAXOSMITHKLINE | 20,67 | +1,20 % | From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers |
| SANOFI | 86,44 | +1,95 % | S&P Equity hebt Ziel für Sanofi auf 92 Euro - 'Buy' |
| NOVO NORDISK | 133,55 | +0,49 % | Novo Nordisk and Paula Deen Announce Winners of the Seeing Diabetes in a New Light' Contest |
